[Pubmed] Pembrolizumab-induced myasthenia gravis: A rare immune-related adverse event in a patient treated for bladder c
Posté : 16 oct. 2025 12:00
Urol Case Rep. 2025 Sep 30;63:103226. doi: 10.1016/j.eucr.2025.103226. eCollection 2025 Nov.
ABSTRACT
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1, such as pembrolizumab, are widely used for the treatment of various malignancies. These therapies, while typically less toxic than traditional chemotherapy, are associated with immune related adverse events which may affect the gastrointestinal tract, lungs, skin, liver, and less commonly the nervous system. Neurologic irAE are rare but carry high mortality rates. We present a case of seronegative myasthenia gravis in a patient treated with pembrolizumab for refractory bladder cancer. This case highlights the importance of early recognition of neurologic manifestations of irAE in patients receiving therapy with ICIs.
PMID:41098798 | PMC:PMC12519292 | DOI:10.1016/j.eucr.2025.103226
Source: https://pubmed.ncbi.nlm.nih.gov/4109879 ... t9+e462414